Navigation Links
Sangui Biotech International, Inc., Reports Sales Decrease, Continued Losses
Date:10/22/2008

Shareholders' Meeting to be Held on November 18, 2008

WITTEN, Germany, October 22 /PRNewswire-FirstCall/ -- Sangui BioTech International, Inc., published its financial statements for its fiscal year ended June 30, 2008, on October 21. According to the report on form 10-KSB as filed with the SEC the company yielded sales of its cosmetics and wound management products in the amount of approximately USD 207,000 a decrease of 44% as compared with sales revenues of approximately USD 372,000 in the previous year. The decrease is attributable to the company's focus on product development (new cosmetics series, new surgical application of Chitoskin wound pads) and a lower return on marketing efforts with respect to cosmetic products. This also entailed higher research and development cost as well as an increase in General and administrative expenses.

The company reports a net loss for the year of approximately USD 854,000 (2007 net loss: approximately USD 721,000). The resulting accumulated deficit amounts to approximately USD 23.3 million. Total shareholders' deficit as of June 30, 2006 stands at approximately USD 1.1 million. Net cash used in operating activities of approximately USD 1.1 million was offset by cash inflows from financing activities (net of effects of exchange rates) in the amount of approximately USD 1.4 million.

Operations in the 2008 financial year were financed by investments from several European investors in the amount of approximately USD 994,000. In accordance with US-GAAP the amount is shown as foreign currency translation adjustments in the profit-and-loss statement.

The company invites its shareholders to attend the General Meeting of Shareholders on November 18, 2008 on the premises of the Forschungs- und Entwicklungszentrum in Witten, Germany.

SanguiBioTech GmbH is a wholly owned subsidiary of Sangui BioTech International, Inc. (htp://www.pinksheets.com: SGBI)

Some of the statements contained in this news release discuss future expectations, contain projections of results of operation or financial condition or state other "forward-looking" information. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The forward-looking information is based on various factors and is derived using numerous assumptions. Important factors that may cause actual results to differ from projections include, among many others, the ability of the Company to raise sufficient capital to meet operating requirements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," and variations of such words and similar expressions are intended to identify such forward-looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

For more information please contact:

Joachim Fleing

Phone: +49-160-741-27-17

Fax: +49-2302-915-191

e-mail: fleing@sangui.de


'/>"/>
SOURCE Sangui Bio Tech International Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Sangui Partnership Enters a New Phase:
2. Sangui BioTech International, Inc., Reports Sales Increase, Continued Losses
3. Investors Acquire Share in Sangui BioTech GmbH
4. Sangui BioTech International, Inc. Files Remaining Reports
5. Sangui Bio Tech International Inc. Shareholders Meeting Delayed to Include FY 2008 Report
6. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
7. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
8. ISI Increases West Coast Life Science and Biotech Support for Emerging Companies with Expansion in San Francisco and San Diego
9. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
10. Finkelstein Thompson LLP Announces GPC Biotech AG Investigation
11. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... program for the development of future natural products for crop ... and development center in Israel and ... Stockton has a variety of products adapted to ... in more than 35 counties worldwide. ... product Timorex Gold ® is used to control a ...
(Date:2/6/2016)... ... February 06, 2016 , ... The Center for Excellence in Education ... high school teachers on Wednesday February 10, 2016. This Bite of Science session, ... of Conservation, located at 1500 Remount Road in Front Royal, VA from 5:00 p.m. ...
(Date:2/5/2016)... N.C. , Feb. 5, 2016  In the ... role for a host of launch activities including the ... of this launch activity is especially high in the ... Best Practices and the Role of Medical ... help companies focused on oncology therapies find better ways ...
(Date:2/5/2016)... 5, 2016 Australian-US drug discovery and development company, ... appointment of a new Chairman, Mr John O,Connor , ... immediately. James Garner , has also been ... former Acting CEO, Mr Iain Ross , will resume ... --> James Garner , has also been formally appointed ...
Breaking Biology Technology:
(Date:2/3/2016)... 2016 --> ... "Automated Fingerprint Identification System Market by Component (Hardware and ... & Finance, Government, Healthcare, and Transportation) and Geography - ... is expected to be worth USD 8.49 Billion by ... and 2020. The transformation and technology evolution from the ...
(Date:2/2/2016)... This BCC Research report provides a ... the recent advances in high throughput ‘omic platforms ... forward. Includes forecast through 2019. Use ... opportunities that exist in the bioinformatic market. Analyze ... well as IT and bioinformatics service providers. Analyze ...
(Date:2/2/2016)... MOUNTAIN VIEW, Calif. , Feb. 2, 2016 ... diabetic retinopathy market, Frost & Sullivan recognizes US-based ... North America Frost & Sullivan Award for New ... technology provider in North America ... standard in the rapidly growing diabetic retinopathy market. ...
Breaking Biology News(10 mins):